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Abstract
Background: We posit that the same mononuclear phagocytes (MP) that serve as target cells and vehicles for a host of
microbial infections can be used to improve diagnostics and drug delivery. We also theorize that physical and biological
processes such as particle shape, size, coating and opsonization that affect MP clearance of debris and microbes can be
harnessed to facilitate uptake of nanoparticles (NP) and tissue delivery.
Methods: Monocytes and monocyte-derived macrophages (MDM) were used as vehicles of superparamagnetic iron oxide
(SPIO) NP and immunoglobulin (IgG) or albumin coated SPIO for studies of uptake and distribution. IgG coated SPIO was
synthesized by covalent linkage and uptake into monocytes and MDM investigated related to size, time, temperature,
concentration, and coatings. SPIO and IgG SPIO were infused intravenously into naı ¨ve mice. T2 measures using magnetic
resonance imaging (MRI) were used to monitor tissue distribution in animals.
Results: Oxidation of dextran on the SPIO surface generated reactive aldehyde groups and permitted covalent linkage to
amino groups of murine and human IgG and F(ab’)2 fragments and for Alexa FluorH 488 hydroxylamine to form a Schiff
base. This labile intermediate was immediately reduced with sodium cyanoborohydride in order to stabilize the NP
conjugate. Optical density measurements of the oxidized IgG, F(ab’)2, and/or Alexa FluorH 488 SPIO demonstrated ,50%
coupling yield. IgG-SPIO was found stable at 4uC for a period of 1 month during which size and polydispersity index varied
little from 175 nm and 200 nm, respectively. In vitro, NP accumulated readily within monocyte and MDM cytoplasm after
IgG-SPIO exposure; whereas, the uptake of native SPIO in monocytes and MDM was 10-fold less. No changes in cell viability
were noted for the SPIO-containing monocytes and MDM. Cell morphology was not changed as observed by transmission
electron microscopy. Compared to unconjugated SPIO, intravenous injection of IgG-SPIO afforded enhanced and sustained
lymphoid tissue distribution over 24 hours as demonstrated by MRI.
Conclusions: Facilitated uptake of coated SPIO in monocytes and MDM was achieved. Uptake was linked to particle size and
was time and concentration dependent. The ability of SPIO to be rapidly taken up and distributed into lymphoid tissues also
demonstrates feasibility of macrophage-targeted nanoformulations for diagnostic and drug therapy.
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Introduction
The ability of monocytes to migrate to the sites of inflammation,
infection, and tissue degeneration makes them attractive vehicles
to deliver contrast agents for diagnosis or drugs as therapeutic
modalities [1]. Indeed, the tissue distribution of circulating
monocytes during inflammatory conditions closely parallels sites
of microbial infection [2]. Our laboratory has pursued the
question as to whether monocytes and monocyte-derived macro-
phages (MDM) that disseminate virus in an infected human host
could be used to traffic drugs to tissue sites and combat active HIV
replication [3,4,5,6]. Precedents for cell-based systems already
have been provided for viral gene and drug delivery systems
[7,8,9]. However, obstacles in realizing this goal center on both
cell uptake of drug and monocyte trafficking to tissues known as
sites of disease [10]. On balance, progress was, in part, achieved
towards these ends in our laboratories. First, we demonstrated cell
uptake and distribution of nanoparticles (NP) loaded with anti-
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loading of monocytes and MDM with NP, the cells readily
distribute NP within and throughout body tissues [3]. Third,w e
developed a number of bioimaging, high performance liquid
chromatographic, and histological approaches that can readily
measure both drug and monocyte-macrophage trafficking and
distribution [4,11]. However, one very important component of
this process was lacking; the kinetics of NP uptake and distribution
de novo. Indeed, if any drug is to be used in the clinic, it need be
formulated for parenteral use. Achieving this has proven difficult,
as any NP given would be rapidly distributed to the liver, where it
would be metabolized and degraded.
The numbers of studies that explore such distributions are quite
limited [12]. In the current report, we took advantage of known
monocyte functions to facilitate NP uptake. Indeed, it is well
known that opsonization of particles and microbes facilitates rapid
uptake into monocytes and MDM. We reasoned that NP coating
in a similar manner could achieve similar outcomes. As
approximately 55% of macrophages in lymphoid tissues are
derived from monocyte extravasations [4], we reasoned that if
circulating monocytes could take up immunoglobulin (IgG)-
conjugated NP after intravenous injection, then particle size and
configuration would facilitate monocyte-macrophage uptake. At
least one ‘‘theoretical’’ report of mathematical models on the path
of macrophages from blood and their potential as vehicles for drug
delivery was previously reported [13]. Supporting this idea is a
study demonstrating the accumulation of superparamagnetic iron
oxide (SPIO)-laden NP in monocytes into sites of neuroinflamma-
tion [14]. A number of reasons illustrate the significant advantage
for cell-based NP delivery of foreign particles. First, monocytes are
phagocytic cells and the uptake of micro- and nanosized drug
carriers has widely been demonstrated [15,16]. Second, direct
intravenous injection of NP can facilitate uptake by circulating
monocytes. This approach requires the targeting of monocytes
using ligands that interact with antigens or receptors located on
the immune cell membrane. The opsonization of foreign particles
could facilitate the phagocytic process due to the interaction with
Fc receptors highly expressed on the surface of monocytes [17,18].
Third, a cell-based system can achieve carriage of the NP and limit
sequestration in organs of the reticuloendothelial system such as
the liver. Covalent conjugation of IgG on the SPIO surface affects
accelerated uptake of NP in monocytes and enhanced in vivo
retention without affecting monocyte viability. Fourth, attachment
of ligands did not induce significant variation of the NP surface
charge as was demonstrated with albumin coatings. Our results,
taken together, demonstrate the feasibility of coated NP for drug
delivery into lymphoid tissues. The ability of magnetic resonance
imaging (MRI) to support the feasibility of macrophage-based
drug delivery systems renders these tests useful for tracking NP
therapeutics in human disease.
Methods
SPIO NP and immunoglobulin coatings
Sodium periodate, sodium cyanoborohydride, neocuproine,
ammonium acetate, ascorbic acid and potassium permanganate
were purchased from Sigma-Aldrich, St. Louis, MO. Murine and
human IgG F(ab’)2 and Fc fragments were purchased from
Jackson ImmunoResearch Laboratories, Inc., West Grove, PA.
Rat IgG2a anti- MsCD16/CD32 (FcgRIII/FcgRII) (2.4G2), Rat
IgG2a anti-trinitrophenol (TNP) isotype control, IgG1 anti-Hu
CD16 (FcgRIII) (3G8), IgG1 anti-Hu CD32 (FcgRII) (3D3), IgG1
anti-TNP (107.3) were purchased from BD Biosciences, San Jose,
CA. IgG1 anti-Hu CD64 (FcgRI) (10.1) was purchased from
eBioscience, San Diego, CA. Alexa FluorH 488 carboxylic acid,
succinimidyl ester and Alexa FluorH 488 hydroxylamine were
purchased from Invitrogen. Ferumoxides (Feridex IVH, Berlex
Laboratories, Wayne, NJ) with an average hydrodynamic size of
150 nm and concentration of iron at 11.2 mg/mL were used as
SPIOFeridexH (SPIO) (Bayer Healthcare Pharmaceuticals,
Wayne, NJ) and composed of 11.2 mg of iron per ml of aqueous
matter. NP were concentrated using a Microcon YM-30
centrifugal filter unit (Millipore, Billerica, MA) and dialyzed
against acetate buffer (0.1 M, pH 5.5) overnight at 4uC. Dextran
T-10 surrounding the iron core of SPIO was oxidized by reaction
with 10 mM sodium metaperiodate in the dark for 1 hour at room
temperature. To remove excess reagent, oxidized SPIO were
dialyzed against phosphate-buffered saline (PBS) overnight at 4uC.
Human IgG (Baxter Heathcare Corporation, Westlake Village,
CA) or murine IgG (Jackson ImmunoResearch Laboratories, Inc.)
were added to the oxidized NP suspension in PBS with 50 mM of
sodium cyanoborohydride in 1 M NaOH at final concentrations
of IgG and SPIO of 2 mg/ml and 10 mg/ml, respectively. The
incubation was performed overnight under gentle stirring at room
temperature and the reaction was quenched by addition of 50 mM
Tris-HCl. Free IgG was removed from the NP using Sepharose
CL-4B column. Particle size was measured by dynamic light
scattering. The presence of IgG covalently attached to NP and free
IgG amount were estimated using the micro bicinchoninic acid
(BCA) assay (Pierce Biotechnology, Rockford, IL). In parallel
preparations, Alexa FluorH 488 hydroxylamine, mouse IgG and
mouse and human IgG F(ab’)2 fragments were reacted with
aldehyde SPIO at room temperature in PBS buffer to obtain
control reagents for Fc blocking studies and to synthesize
combined fluorescence and antibody conjugated SPIO prepara-
tions. For fluorescent nanoformulations, Alexa FluorH 488
carboxylic acid succinimidyl ester was conjugated with IgG SPIO
in carbonate-bicarbonate buffer for 2 h. The free dye was
separated from conjugates using PD-10 columns.
Monocyte, MDM, and bone marrow-derived macrophage
(BMM) isolation and cultivation
Human monocytes were obtained by leukopheresis from HIV-1
and hepatitis seronegative donors and were purified by counter-
current centrifugal elutriation. Wright-stained cytospins were
prepared and cell purity assayed by immunolabeling with anti-
CD68 (clone KP-1). To generate MDM, elutriated monocytes
were cultivated for up to seven days at a concentration of 2610
6
cells/ml at 37uC in a humidified atmosphere in Dulbecco’s
modified Eagles medium (DMEM) supplemented with 10% heat-
inactivated pooled human serum, 1% glutamine, 50 mg/ml
gentamicin, 10 mg/ml ciprofloxacin and 1000 U/ml recombinant
human macrophage colony stimulating factor (MCSF), a generous
gift of Wyeth Inc., Cambridge, MA [3–5]. Male BALB/c mice
(Charles River Laboratory, Inc., MA), 4–5 weeks of age were used
as BMM donors. The femur was removed, the bone marrow
expelled, cells dissociated into single cell suspensions and cultured
for 10 days supplemented with 1000 units/ml of MCSF (Wyeth,
Inc.). Cultured BMM proved to be 98% CD11b
+ by flow
cytometric analysis using a FACS Calibur flow cytometer (BD
Biosciences).
Studies of formulated SPIO uptake into monocytes and
macrophages
For study, human monocytes or MDM were transferred in 8-
well Lab-Tek II chamber slides (0.5610
6 cells/well). SPIO were
added to a final iron concentration of 0.5 mg/ml and incubated
Nanoparticles and Monocytes
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paraformaldehyde for 30 minutes at room temperature. For the Fc
blocking studies human IgG Fc fragment or anti-Fc receptor
antibodies (clones 3G8, 3D3 and 10.1) (10 ug/ml) were added to
MDM cultures, incubated at 37uC for 20 minutes followed by the
incubation of SPIO, IgG-SPIO, or F(ab’)2-SPIO to a final iron
concentration of 0.5 mg/ml for 0.5, 1, 2 and 4 hours. Cells with
media alone and with anti-TNP isotype control, 107.3 served as
controls. For murine BMM, the procedure was identical to the
human cells but mouse IgG Fc fragment and IgG FcgRIII/FcgRII
were used as Fc blockers. After 26PBS washes cells were observed
by fluorescence microscopy. The iron content was estimated by
ferrozine (see below). Presence of iron was observed by Prussian
blue staining with 5% potassium ferrocyanide and 5% hydrochlo-
ric acid. After three washings, cells were counterstained with
nuclear fast red. Viability of monocytes and MDM was estimated
by a live/dead assay (Axxora, LLC, San Diego, CA). Iron labeled
monocytes were incubated with a mixture of 0.5 mM of ethidium
homodimer-1 with 1 mM of calcein AM at 37uC under humidified
atmosphere for 25 minutes. The cells were washed three times,
fixed with 4% paraformaldehyde for 30 minutes at room
temperature, and observed by fluorescent microscopy. Calcein-
AM accumulation and cleavage by cytosolic esterase labels live
cells green and ethidium homodimer-1 labels the nuclei of dead
cells red. Cell viability was confirmed by trypan blue exclusion
wherein iron-labeled human monocytes were incubated with
trypan blue for 15 minutes and washed three times. Unlabeled
cells and human monocytes that were killed using a 70% methanol
solution served as controls. For transmission electron microscopy
(TEM), human monocytes and MDM were cultivated on poly-d-
lysine-coated Thermanox coverslips (Thermo Fisher Scientific,
Rochester, NY), incubated with SPIO during 1 hour at 37uC, and
washed three times with phosphate buffered saline. They were
fixed in 2% glutaraldehyde, 2% paraformaldehyde, 0.5% acrolein
in 0.1 M Sorensen’s phosphate buffer pH 7.2, and were post-fixed
in 1% osmium tetroxide in water for 30 minutes. After washing,
human monocytes were dehydrated for 5 minutes at each step in a
graded series of ethanol solutions and infiltrated with araldite
embedding media by passing through a graded series of ethanol/
araldite solutions. Coverslips were embedded culture side face
down onto blank araldite discs, placed overnight in an oven at
65uC for polymerization, and removed by dipping in liquid
nitrogen. Monocyte and MDM colonies were cut out and
mounted en face for ultra thin sectioning. Sections were placed
on 200 mesh copper grids, and grids were stained with 1% uranyl
acetate and Reynold’s lead citrate. Cells were examined with a
Philips LS410 TEM operated at 80 Kv.
Iron content was estimated using a colorimetric ferrozine assay
[19]. For this assay, duplicate batches of human monocytes and
MDM were cultivated in 24-well plates (1610
6 cells/well). SPIO
were incubated at a final concentration of 0.5 mg/ml for 0.5, 1, 2,
4 and 8 hours, at 4uC and 37uC. Iron-labeled cells were washed
three times with PBS and lysed with 50 mM NaOH for 1 hr at
room temperature on a shaker. Aliquots of cell lysates were mixed
at equal volumes with 10 mM hydrochloric acid (HCl) in order to
dissolve the SPIO. An iron releasing-reagent, a mixture of 1.4 M
HCl and 4.5% (w/v) KMNO4 in distilled water, was added to the
lysates and the mixtures were incubated for 2 hour at 60uC.
Ferrozine assay reagents were prepared in distilled water from
6 mM ferrozine, 2.5 M ammonium acetate, 1 M ascorbic acid
and 6.5 mM neocuproine pre-dissolved in methanol. The samples
were transferred to a 96-well plate and read at 540 nm. Iron
standards were prepared under the same reaction conditions using
a stock solution of iron at 0.2 mg/ml (Ricca Chemical Company,
Arlington, TX). Iron concentration values were normalized to
protein concentrations as determined by the micro BCA assay
(Pierce Biotechnology). T2 relaxivity measurements of iron-labeled
human monocytes were also performed by MRI analysis of
triplicate samples for each time-point. SPIO-labeled cell phantoms
were prepared as 100 ml of 0.5610
6 cells/ml suspended in 100 ml
2% agarose in 200 ml plastic tubes.
Animal studies for SPIO and IgG SPIO tissue distribution
Male BALB/c mice (Charles River Laboratory, Inc., Wilming-
ton, MA), 5–8 weeks old were used for all experiments. Animals
were housed in sterile microisolator cages and maintained in
accordance with ethical guidelines for the care of laboratory
animals of University of Nebraska Medical Center and the
National Institutes of Health. Mice were injected with SPIO or
IgG-SPIO at either 12.5 mg/0.2 ml/mouse or 62.5 mg/0.2 ml/
mouse intravenously via the tail vein. The recommended dose for
a human adult or adolescent is 560 mg/kg. Two groups of mice
with 3–5 animals per group were used for in vivo analyses. SPIO
and IgG-SPIO treated groups were imaged before injection,
continuously for 4 hours after injection, and again at 24 hours.
Mice were injected within 24 hours following preparation of
conjugated SPIO.
MRI for monocyte-macrophage tissue distribution
SPIO particle accumulation in tissue causes an increase in the
magnetic spin-spin relaxivity (R2) of tissue water, which is field-
dependent. Measures of spin-spin relaxivity using two 7T MRI
systems (Bruker 21 cm Biospec/16 cm Pharmascan systems
operating Paravision 4.0) demonstrated in SPIO-labeled cell
phantoms that relaxivity is related directly to cell density.
Measures of relaxivity can track cell uptake and has been used
to track the migration of cells to liver, kidney and spleen after
injection [11]. High-resolution, multislice multi-echo CPMG
phase cycled T2 mapping MRI scans of mouse body were
acquired using a 25-mm birdcage volume coil covering a region
from the neck to the hips with acquisition parameters of echo time
(TE)=10, 20, 30, 40, 50, 60, 70, 80 ms, repetition time
(TR)=4650 ms, number of averages (NA)=4, field of
view=40640 mm with a resolution of 2566128 (voxel si-
ze=1566312 mm), reconstructed to 2566256, 50 interleaved
contiguous 1 mm thick slices, total acquisition time=39 minutes.
Signal intensity was normalized to an external standard to account
for signal drift over time. SPIO accumulation was determined by
changes in R2 (1/T2) within selected regions of interest. After the
injection of SPIO or IgG SPIO, T2 maps were acquired every
40 minutes for 4 hours, and at 24 hours. Intensities of the regions
of interest in spleen, liver and kidney from the even numbered
echoes (accurately refocused in CPMG phase cycled echo trains)
were fit to an exponential decay with a minimum to match the
noise level measured in the images. Data quality was monitored by
the T2 determination of external standards in each set of images.
Histological evaluations
Spleens and livers were collected at 4 and 24 hours after SPIO
or IgG-SPIO administration. Immediately after MRI, tissues were
fixed by perfusion with 4% paraformaldehyde, post fixed for
24 hours, embedded in paraffin and cut into 5 mm thick sections
for histological analysis. For Prussian blue staining, slide mounted
sections were deparaffinized, rehydrated, and reacted for 30 min-
utes in 2% potassium ferrocyanide and 3.7% hydrochloric acid to
visualize ferric iron particles by Prussian blue. Stained sections
were washed and counter stained with nuclear fast red to provide
histological cellular distributions. Images were obtained by
Nanoparticles and Monocytes
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software (Goleta, CA) and processed by AdobeH Photoshop 7.0
software.
Results
SPIO Conjugates
The oxidation of dextran located on the surface of SPIO
generated reactive aldehyde groups. The carbonyls reacted
spontaneously with the amino groups of IgG to form a Schiff
base. This labile intermediate was immediately reduced with
sodium cyanoborohydride in order to stabilize the bond between
the protein and the NP. The IgG-SPIO was then purified using a
Sepharose CL-4B column. Alexa FluorH 488 hydroxylamine was
reacted with aldehyde SPIO to synthesize combined fluorescence
and IgG conjugated SPIO. The free dye was separated from
conjugates using PD-10 columns. BCA reagent was added to each
collected fraction and the optical density (OD) was measured at
540 nm. Sepharose CL-4B chromatography of NP conjugate
reactions showed that NP eluted between 20 ml and 25 ml and the
free IgG between 45 ml and 60 ml (Figure 1, top). SPIO reacted
with IgG yielded higher BCA reactivity compared to control SPIO
due to the presence of increased protein moieties, while the
proportion of free IgG in the second peak was lower. The coupling
yield was estimated at ,50%. These differences were not observed
when aldehydic groups were blocked with excess amines.
Additionally, the elution profile of oxidized and amine-blocked
SPIO incubated with IgG was similar to that of free SPIO (data
not shown). That the BCA reactivity of eluted SPIO did not
approach baseline suggested the possible interference of the
dextran coating the SPIO. The stability of IgG-SPIO was studied
at 4uC at selected time points for a period of one month by
measures of size and polydispersity index (Figure 1, bottom).
Immediately after conjugation, IgG-SPIO was 175 nm in size and
had a polydispersity index of approximately 0.2. No significant
changes in hydrodynamic diameter and the size distribution were
noticed during the first two weeks. However, 30 days after
conjugation, IgG-SPIO increased up to 270 nm and the
polydispersity index approximated 0.3 suggesting limited NP
aggregation.
Monocyte uptake of SPIO NP
Purified IgG-SPIO and unconjugated SPIO were incubated at
37uC with human monocytes at a final iron concentration of
0.5 mg/ml. Cellular iron content was detected with Prussian blue
staining and the cells were counterstained with nuclear fast red
(Figure 2A and B). A high accumulation of iron was observed with
IgG-SPIO; whereas, the uptake of native SPIO by human
monocytes was limited. The viability of iron-containing monocytes
was then studied using both a live/dead assay (Figure 2C) and
trypan blue staining (Figure 2D). After a 25 minute exposure with
calcein-AM and ethidium homodimer-1 (EthD1), human mono-
cyte viability was consistently .90% as characterized by green
fluorescence labeling. Similarly most of the iron-labeled monocytes
excluded trypan blue confirming that internalization of IgG-SPIO
did not induce a toxic effect. Transmission electron microscopy
(TEM) was used to study the location of SPIO in human
monocytes (Figure 2E and F). Accumulation of chromatin was
observed in the nuclear periphery of human monocytes. IgG-
SPIO was taken up in cells within endocytic vesicles with size
reaching 0.7–1 mm. Distribution of IgG-SPIO was intracytoplas-
mic with preferential location of NP on small membrane ruffles.
Both the number and the size of iron-loaded vesicles were
increased in the IgG-SPIO formulations.
Cellular iron content was assessed using a colorimetric ferrozine
assay and by MRI after washing and lysis of cells. Values were
normalized by estimation of the protein concentration (Figure 3,
top). Covalent attachment of human IgG accelerated SPIO uptake
as determined by colorimetric assays. After 1 hour, the iron
content of cells, ,0.2 mg iron/mg protein, reached half of the
maximum value. In contrast to IgG-SPIO, the internalization of
SPIO versus time was linear until 8 hours of incubation, passing
from ,0.03 to 0.06 mg iron/mg protein between 4 and 8 hours.
For the majority of times investigated, NP content was nearly an
order of magnitude higher than that of cells treated with uncoated
NP. In parallel, MRI was used to detect the labeling of monocytes
and ensure that the coupling procedure did not alter the NP
magnetic properties (Figure 3, bottom). Labeled human monocytes
were suspended in 2% agarose and the relaxation time T2 was
measured. In accordance with the previous experiment, the iron
uptake was drastically improved when human monocytes were
exposed to IgG-SPIO. Maximal levels of SPIO were reached after
a 4 hour-incubation. Despite the oxidation step, the relaxation
properties of IgG-SPIO were preserved.
To test the effect of size and dextran coating on cellular uptake,
SPIO coated with 100 kDa dextran with sizes ranging from 62 to
394 nm were incubated with human monocytes for 1 hour at
37uC (Figure 4A). A greater iron uptake was detected for the
largest NP with the same molecular weight of dextran. However,
despite a lower size, SPIO coated with 10 kDa-dextran (FeridexH)
were taken up in monocytes at a higher level than other NP coated
with 100 kDa-dextran. Considering that the phagocytosis process
is mediated by adsorption of serum proteins, the molecular weight
of dextran is a crucial parameter for the adsorption of opsonins
and consequently, the uptake of NP. In the nanometer range, the
size effect on the opsonisation is much less important than the
hydrophilic coating. After 1 hour-oxidation, SPIO was conjugated
with different concentrations of IgG (0.5, 1, 2 and 4 mg/ml) and
each conjugate IgG-SPIO complex was incubated with human
monocytes for 0.5 and 1 hr at 37uC. Cellular uptake of IgG-SPIO
prepared at different IgG concentrations was not drastically
different after incubation with monocytes for 0.5 and 1 hour
(Figure 4B). These results suggested that either the cell surface was
saturated by SPIO or that internalization is not dependent on
ligand density. Non-covalent attachment of IgG did not induce an
enhanced uptake for these specific experiments (Figure 4C).
Nonetheless, the steric barrier generated by the dextran surround-
ing the iron core of NP could have prevented adsorption of IgG.
IgG-SPIO uptake was partially inhibited when incubation was
performed at 4uC (Figure 4D). Next, IgG-SPIO uptake by
monocytes and MDM were compared and found to be virtually
equal for both cell types (Figure 4E). The results support the idea
that similar mechanisms for iron uptake were operative amongst
both cell types. In order to study the mechanism of internalization,
IgG-SPIO and free IgG, at a concentration of 1 mg/ml, were co-
incubated with human monocytes (Figure 4F). No significant
differences were detected after the blocking of monocyte Fc
receptors with free IgG. These results suggested an Fc receptor-
independent mechanism for IgG-SPIO cell entry. To test that
possibility, human serum albumin (HSA) was covalently attached
to SPIO using the identical oxidation/reduction procedure as IgG
conjugation. Similar to IgG, HSA significantly enhanced the
uptake of SPIO (Figure 4G). In order to confirm the notion that
particle uptake was independent of the Fc receptor we performed
blocking studies. Regression analysis of intracellular iron of IgG-
SPIO and F(ab’)2-SPIO uptake by MDM over 4 hours of co-
culture showed no differences in uptake kinetics (P=0.271),
indicating that the presence of the IgG Fc portion provided no
Nanoparticles and Monocytes
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differences in IgG-SPIO uptake kinetics were discernable by
treatment of MDM with human Fc fragments, anti-Fc receptor-c
antibodies (CD16/CD32/CD64), or isotype control antibody
compared to untreated MDM (P=0.624). Additionally, results in
human MDM were validated in mouse BMM wherein no
differences were observed in uptake kinetics of mouse IgG-SPIO
by BMM treated with mouse Fc fragments, rat anti-mouse Fc
receptor-c (CD16/CD32), or rat isotype control antibody
compared to untreated BMM (P=0.988). These results confirmed
the hypothesis that the internalization of IgG-SPIO was not Fc-
receptor mediated. Although internalization of HSA-SPIO was
similar to IgG-SPIO, the iron content in human monocytes was
higher in monocytes incubated with IgG-SPIO than HSA-SPIO.
This could be due to the fact that HSA modified the conjugated
SPIO itself. To test the latter possibility, physical-chemical
properties of SPIO including zeta potential and size measurements
of the nanoparticles were performed in HEPES buffer at pH 7.4.
HSA modifications of the SPIO did not affect its size (Figure 4H).
In addition, the zeta potential of NP did not significantly change
after ligand attachment; thus, SPIO remained negatively charged.
SPIO and IgG SPIO tissue distribution
To assess comparative tissue distribution of SPIO and IgG-
SPIO, we injected NP intravenously into naı ¨ve mice. A cartoon of
the technique with proposed distributions into lymphoretricular
structures is shown in Figure 5. Both IgG-SPIO and Alexa FluorH
488 hydroxylamine IgG-SPIO nanoformulations were used in
study. Following intravenous injection, tissue biodistribution of
SPIO was tracked by MRI over the first 4 hours and at 24 hours
post-injection. MRI tests revealed both hepatic and splenic
accumulations of IgG-SPIO demonstrating higher levels for each
post-injection time point in the spleen and liver at lower
concentrations of injected NP (12.5 mg, n=6, Figure 6 A, C,
and E) as well as in representative images in Figure 7. However, at
the higher concentration (62.5 mg, n=5), results were identical
between SPIO and IgG-SPIO injected mice (Figure 6 B, D, and
F), supporting the notion that NP saturated the lymphoreticular
Figure 1. Manufacture, column elution and characterization of IgG SPIO. Top: Sepharose 4B-CL elution profile of IgG-SPIO after incubation
of IgG with oxidized SPIO (closed circles). Controls were performed with IgG incubated with non-oxidized SPIO (closed squares) as well as oxidized
SPIO blocked by addition of an excess of amine groups (open circles). Bottom: Size and polydispersity index measurements of IgG-SPIO at different
time points after the conjugation and storage at 4uC.
doi:10.1371/journal.pone.0004343.g001
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areas in spleen and diffusely in the liver. Uptake of SPIO was seen
in circulating blood monocytes (data not shown) and tissue
macrophages by analysis of tissue specimens from spleen and liver
of animals that were injected with Alexa FluorH 488 hydroxyl-
amine IgG-SPIO nanoformulations following the MRI tests
(Figure 8).
Discussion
The objective of our research efforts is to substantively improve
drug delivery through the use of cell based carriers for tumors and
microbial infection, in particular HIV [1]. Our focus has over the
past quarter century addressed MP as reservoirs and vehicles for
dissemination of virus and as such led us to explore whether the
Figure 2. Mechanisms and cell viability for IgG SPIO monocyte uptake. Human monocytes were incubated for 1 hour at 37uC with SPIO (A)
or IgG-SPIO (B) at a concentration of 0.5 mg iron/ml. Iron was stained by Prussian blue technique and cells were counterstained with nuclear fast red.
Toxicity of IgG-SPIO was evaluated after 1-hour incubation with human monocytes. Viability of iron-labeled monocytes was assessed using a live/
dead assay with calcein-AM and ethidium homodimer-1 (EthD1) (C). Calcein-AM accumulation and cleavage by cytosolic esterase labeled live cells in
green and EthD1 labeled dead cells in red. Trypan blue exclusion was used as a dual control (D). Internalization of IgG-SPIO was observed by TEM.
IgG-SPIO labeled monocytes were observed at 4,4006(E) and 10,4006(F) magnifications. The arrowheads show the SPIO within the cell cytoplasm.
doi:10.1371/journal.pone.0004343.g002
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[22,23]. In order to test these hypotheses, four critical milestones
had to be achieved. First, we needed to manufacture NP that could
rapidly enter MP and be taken to infected tissue reservoirs. Second,
the drugs needed to be released from carrier cells in a continuous
manner over time periods measured in weeks. Third, the uptake,
transport, and release needed to occur without notable system
toxicity. Fourth, sustained transport of cells needed to take place
beyond the liver and particle clearance seen in lymphoid tissues
including the spleen. To achieve the latter goal, we used a simple
means, antibody opsonization, to facilitate uptake of particles into
MP; the process by which the host facilitates foreign particles for
ingestion and destruction. We reasoned that this process might
also be used to coat NP. Indeed, the binding of a pathogen by
antibody to a receptor on the cell membrane can promote
macrophage uptake through Fc receptors [24]. Alternatively, the
complex would stimulate the phagocyte nonspecifically and in this
manner membrane alterations would occur without changes in
membrane properties to facilitate uptake [25]. The receptor-opsin
NP complex [26] would create byproducts that could include C3b
and C4b and other components of the complement system. These
would be deposited on the cell surface of the antibody linked NP
and positively affect its uptake.
Nonetheless and regardless of the mechanism, our results
demonstrated that coating of NP enhanced uptake and positively
affected NP biodistribution, making the coated NP an attractive
candidate for drug delivery. It is likely that circulating monocytes
were able to take up NP and as such, deliver them to the spleen
rather than simply clearing the particles through the liver. There is
precedent for this as monocytes are known to incorporate micro-
and nano-sized drug carriers (such as liposomes or nanoparticles)
and act as Trojan horses by crossing the brain and enabling drug
delivery [27,28,29]. Moreover, it was shown that during
neurological diseases (such as Parkinson’s and Alzheimer’s
diseases, meningitis, viral encephalitis, Prion disease, and HIV-1
associated neurocognitive disorders) monocyte brain migration
can occur based on the generation of chemotactic gradient
facilitated by inflammation [30]. This occurs in a broad range of
infectious, neoplastic, and degenerative disorders whereby inflam-
mation occurs in tandem with extensive leukocyte recruitment.
Monocytes and macrophages have the unique ability to migrate to
sites of inflammation through diapedisis and chemotaxis [31].
Other abilities of these cells include phagocytosis of foreign
particles, production of cytotoxic compounds, and subsequent
release of those compounds by exocytosis making myeloid lineage
cells attractive candidates for cell based NP carriage of drug [1,2].
There are many examples that MP may be used for drug
delivery. They are first and foremost capable of endocytosing
colloidal nanomaterials and subsequently releasing them into
surrounding media [27,29]. A method used to increase the
migration of these cells to the brain is to package magnetic
particles along with drug inside liposomes, then apply a local
magnetic field to the head [29]. MP seem to prefer negatively
charged compounds as they preferentially uptake liposomes
containing negatively charged lipids or liposomes modified by
poly-anions [28]. This offers a possible strategy to modulate the
uptake and release of nanomaterials. Liposomes containing
phosphatidylserine (a negatively charged lipid) and loaded with
chloroquine were shown to accumulate within macrophage
phagolysosomes and greatly increase the therapeutic activity
against chronic fungal infection when compared to high doses of
free drug [32].
One attribute of immune cells is the ability to home to diseased
sites, thus representing the raison d’etre to design NP for direct
uptake. Immediately after ex vivo manipulation and re-implanta-
tion, the majority of macrophages accumulate in the lungs, liver,
and spleen rather than to the targeted diseased tissue. However,
having circulating monocytes uptake NP, migrating successfully to
target tissues [33] would allow drug-laden cells to reach the target
site. Once the cell loaded with NP has reached the site of interest,
drug could be released to the extracellular space or internalized by
the target cell. By this method, drugs with intracellular action that
are incapable of crossing cell membranes can be assisted in
reaching their target cells or tissue. Cellular uptake mechanisms
vary according to cell type, physicochemical properties of the
compound, and the mechanism of drug activation [34,35].
Intracellular targeting is feasible through the use of ligands that
trigger receptor-mediated endocytosis.
The option we used is to modify the surface of nanocarriers (for
example by coating the surface of the particle in IgG) to induce or
enhance cell uptake. It has been shown that NP uptake is both
concentration and time dependent. For example, PLGA NP were
transported into primary endosomes and sorted to either recycling
endosomes or secondary endosomes [36]. In the acidic environ-
ment of the secondary endosome, the NP surface changes from
anionic to cationic leading to the escape of the NP into the
cytoplasm. Previous studies showed that when nanoparticles were
delivered locally, drug levels in tissues could be sustained for up to
7–14 days [37,38]. In a study where pentamidine-laden NP were
administered to Leishmania infected mice, ultrastructural examina-
tion showed NP trafficking inside Leishmania infected Kupffer cells.
In these cells, the NP were located within vacuoles and primary
lysosomes, which form into secondary lysosomes. Secondary
Figure 3. Intracellular iron levels by MRI phantoms after SPIO
and IgG-SPIO monocyte uptake. Internalization kinetics of IgG-SPIO
and SPIO at iron concentrations of 0.5 mg/ml were determined in
human monocytes incubated at 37uC. (A) Estimation of the iron loading
by ferrozine assay (top) and by measurement of the relaxation (R2) of
iron-labeled monocytes (bottom).
doi:10.1371/journal.pone.0004343.g003
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observed [39].
Prussian blue staining of tissue sections was performed in liver
and spleens of MRI tested animals, but showed discordant results.
One potential confounding factor is the elimination of vascular
and perivascular cells during perfusion. Indeed, the circulating
monocytes and macrophages were the sole contribution to the
signal changes observed in the kidney, which did not sequester
cells in steady state. It is also possible that oxidation of SPIO
during perfusion and tissue processing could prevent binding of
Prussian blue. In addition, tissue sampling, especially in the liver
where the distribution was noticeably heterogeneous, could result
in broad variability in cell numbers assayed from histological
sections. As a result, the quantification of Prussian blue in tissue is
under further investigation.
Previous studies performed in our laboratory using indinavir
(IDV) nanosuspensions highlighted the importance of cell-based
drug delivery for HIV treatment [3,4,5]. These experiments
revealed that anti-retroviral NP laden BMM can carry and release
drug in tissue. After intravenous injection of NP-IDV BMM, tissue
and sera IDV levels were sustained above the effective dose 50
(ED50) and elicited reductions in numbers of virus-infected cells.
However, no studies to date have assessed the rapid and sustained
success towards the ability of directly administered NP to be taken
up by monocytes and macrophages and be distributed to lymphoid
sites.
We used SPIO as a standard test nano-probe to study cell based
uptake and carriage. The rationale is based on the fact that
similarly sized and configured particles could be used for cell based
drug delivery to treat a host of degenerative and infectious
disorders. SPIO are taken up readily into monocytes and MDM
and do distribute to tissue. Indeed, a study reported by Engberink
et al. [14] showed the accumulation of SPIO-laden monocytes in
neuroinflammation sites. Thus, the use of the immune system to
target inflamed tissue represents a promising cell-based strategy to
transport NP to targeted cells. The other advantage is to prevent
interaction of foreign particles with the host environment, thus
prolonging their systemic half-life. For optimal utilization of
macrophage delivery systems, uptake of NP within minutes must
be achieved along with the accurate assessment as to whether cells
reach a targeted distribution. In this study, we explored the
feasibility of utilizing direct injections. A necessary step toward
Figure 5. Schematic diagram for IgG SPIO NP cell tissue delivery. We posit that NP can be efficiently taken up by circulating blood borne
monocyte-macrophages in ways that are not toxic to the cell function or mobility. The NP loaded cells are then transported to areas of the lymphoid
and reticuloendothelial system (for example, liver and spleen) and secreted through the kidneys.
doi:10.1371/journal.pone.0004343.g005
Figure 4. NP size and molecular weight on SPIO uptake into monocytes and MDM. Influence of the size of nanoparticles and the molecular
weight of dextran on the uptake of SPIO (A). Uptake by human monocytes of IgG-SPIO with different IgG densities (B) and of native SPIO co-
incubated with free IgG (C). Uptake in human monocytes of IgG-SPIO incubated at 4uC and 37uC (D) and comparison between human monocytes and
MDM (E). Uptake in human monocytes of IgG-SPIO co-incubated with excess of free IgG (F) and of SPIO conjugated to human serum albumin (HSA)
instead of IgG (G). Panel H shows the influence of the oxidation and of the covalent attachment of IgG and HSA on the size and the surface charge of
SPIO. Error bars are SEM.
doi:10.1371/journal.pone.0004343.g004
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elucidation of the charge, size and geometry of the particle itself.
These were accomplished in this investigation including the
measurement of macrophage migration and homing to ensure the
adequacy of reticuloendothelial distribution. In addition, mono-
cytes are phagocytic cells and uptake of micro- and nano-sized
drug carriers has widely been demonstrated [29]. We posit that the
loading of monocytes could be performed by direct intravenous
injection of NP. This approach requires the targeting of monocytes
using ligands interacting with antigens or receptors located on the
immune cell membrane. Opsonization of foreign particles
facilitates the phagocytosis process. Thus, non-specific human
IgG was attached on the surface of SPIO. However, IgG-coated
nanoparticles also will be recognized by tissue macrophages and
rapidly removed from the bloodstream. The carrier should be able
to target circulating monocytes, before sequestration in organs of
the reticuloendothelial system such as the liver and the spleen. Due
to the large number of common antigens and receptors on
monocytes and macrophages, this would have been a common
confounding issue regardless of ligand utilized. This limitation
could limit the clinical utility of nanoparticles for human use and
remains an area of active research in our laboratories.
In the current study, IgG was covalently conjugated to SPIO
using an oxidation/reduction procedure. A simple incubation of
antibodies with SPIO did not allow the adsorption of a significant
amount of IgG. This is due to the steric barrier of dextran
surrounding the iron core of the SPIO. This protein-resistant effect
was dependent on the molecular weight of dextran. Monocyte
uptake of SPIO coated with 100 kDa dextran was lower than that
of 10 kDa dextran-coated SPIO, even for the smaller sized SPIO.
Covalent conjugation of IgG on the SPIO surface accelerated and
increased uptake in monocytes by a factor of 10. After a 30 minute
Figure 6. Quantitation of in vivo IgG SPIO and SPIO tracking using CPMG phase cycled T2 mapping MRI. Change in relaxivity (R2=1/T2)
in the spleen (A, B), liver (C, D) and kidney (E, F) after injection of SPIO (red) or IgG-SPIO (green) into the tail vein of the mouse. Injections of 12.5 mg (A,
C, E) (n=6) and 62.5 mg (B, D, F) (n=5) show higher uptake in circulating monocytes with IgG coating at the lower concentration by 0.5 h post-
injection and times thereafter (p,0.05 two way repeated measures ANOVA for effect of time and SPIO type for spleen and liver). At the higher
62.5 mg dosage, no differences in uptake of SPIO vs. IgG-SPIO at any time were observed.
doi:10.1371/journal.pone.0004343.g006
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than that of native SPIO even after 8 hour co-culture. T2
relaxivity measurements of labeled monocytes confirmed the
enhanced cellular uptake using IgG coating. Besides, oxidation of
dextran did not significantly affect the magnetic properties of
SPIO. The rapid uptake suggests that coated nanoparticles could
be taken up by monocytes within a few minutes after their
intravenous administration. Although internalization of IgG-SPIO
by immune cells was diminished at 4uC demonstrating energy
dependency, monocyte uptake was not inhibited after blocking Fc
receptors with free IgG, thus demonstrating an Fc receptor-
independent mechanism. In addition, replacement of IgG by HSA
significantly increased NP uptake compared to unconjugated
SPIO. The attachment of ligands did not induce a significant
variation of the surface charge of NP and consequently cannot
improve interaction with scavenger receptors responsible for
macrophage uptake of charged nanoparticles. Since free IgG or
HSA-SPIO were unable to totally block uptake, the possibility
remains for yet undefined mechanisms to account for NP uptake;
possibly, one whereby SPIO mediate immune response activation.
Taken together, this report is a first step toward demonstrating
feasibility of coated NP for monocyte uptake and drug delivery.
Moreover, these results suggest the plausibility of drug-ladened NP
uptake by circulating mononuclear cells for distribution of
nanoformulated drug to lymphoid tissues. If achieved, such
modalities could provide substantive progress toward the potential
to improve pharmacokinetics by delivering drugs to tissue sites
where disease is operative and as such, reduce morbidity and
improve clinical outcomes in affected people. In addition, uptake
by circulating mononuclear cells of coated NP tagged with contrast
agents will provide a non-invasive method of detecting regions of
inflammation using other imaging methods, including single
photon emission computed tomography.
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